2 results
424B5
SEEL
Seelos Therapeutics Inc
26 Jan 21
Prospectus supplement for primary offering
5:11pm
corporate purpose and to advance the development of our product candidates.
The precise amount and timing of the application of these proceeds
424B5
SEEL
Seelos Therapeutics Inc
25 Jan 21
Prospectus supplement for primary offering
4:16pm
. The proceeds from the issuance of the Notes have been used for general corporate purpose and to advance the development of our product candidates
- Prev
- 1
- Next